Streetbeat News

Stock Prices

LPLA

Morgan Stanley analyst Michael Cyprys upgraded LPL Finl Hldgs (NASDAQ:LPLA) from Equal-Weight to Overweight and increased the price target from $254 to $315.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:01 pm

EMN

Eastman Chemical (NYSE:EMN) has received mixed reviews from 7 financial analysts over the past quarter, with recent ratings ranging from bullish to indifferent. The average 12-month price target for EMN has been raised to $100.0, up 5.26% from $95.00, with individual targets ranging from $89.00 to $121.00. Analyst actions include both upgrades and downgrades, reflecting changing market dynamics and company performance. Despite a -7.0% decline in revenue growth as of December 31, 2023, Eastman Chemical boasts a strong net margin of 14.05% and excels in ROE and ROA, indicating robust financial management and effective asset utilization.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 12:00 pm

PPG

7 analysts have recently reviewed PPG Industries (NYSE:PPG), showing mixed sentiments. The average 12-month price target is now $158.14, down 2.78% from the previous target. Analysts from Keybanc, UBS, Barclays, RBC Capital, and Baird have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. PPG Industries, a global coatings producer, has shown positive financial performance with a revenue growth rate of 3.94% as of December 31, 2023, and strong profitability indicators such as a net margin of 2.07% and ROE of 1.16%.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 12:00 pm

NDAQ

Morgan Stanley analyst Michael Cyprys has upgraded Nasdaq (NDAQ) from Equal-Weight to Overweight and increased the price target from $59 to $80.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:59 am

CVX

IYE

TTE

XLE

Chevron Corporation (NYSE:CVX) has officially exited Myanmar's Yadana gas field, redistributing its 41.1% stake to PTT Exploration and Production and Myanma Oil and Gas Enterprise. This move comes after Chevron's 2021 announcement to leave Myanmar due to violence and human rights abuses following the 2021 coup. The Yadana field, a significant gas producer, has been a point of contention amid Myanmar's ongoing crisis. Chevron's exit aligns with its commitment to an orderly withdrawal, reflecting on international law and sanctions. Investors can track Chevron's performance through SPDR Select Sector Fund – Energy Select Sector (NYSE:XLE) and iShares U.S. Energy ETF (NYSE:IYE).

Portfolio Pulse from Lekha Gupta

April 09, 2024 | 11:58 am

WISA

WiSA Technologies shares are trading lower despite the Nasdaq accepting its compliance plan. This indicates investor concerns or lack of confidence in the company's ability to maintain compliance or improve its financial health.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:57 am

BGS

K

SPTN

Wall Street's most accurate analysts have provided their views on three high-dividend yielding stocks in the consumer staples sector: Kellanova (K), SpartanNash Company (SPTN), and B&G Foods, Inc. (BGS). These stocks are considered defensive, offering investors stability through high dividend yields during market turbulence. Analyst ratings and price targets have been updated, reflecting a mix of hold, neutral, and underweight positions, with adjustments to price targets both upwards and downwards.

Portfolio Pulse from Avi Kapoor

April 09, 2024 | 11:56 am

BTCUSD

Crypto analyst Michaël van de Poppe suggests Bitcoin could retest its all-time high if it remains above $69K. Currently, Bitcoin is trading at $70,773.87. Van de Poppe's insights come amid a significant rally in Bitcoin, with the crypto community closely watching its performance. The potential for Bitcoin to hit $125,000 before 2025 is discussed, alongside warnings from Arthur Hayes about a possible market firesale due to the Bitcoin halving and Federal Reserve policies.

Portfolio Pulse from Benzinga Neuro

April 09, 2024 | 11:55 am

ALKS

Alkermes shares surged following the announcement of positive topline results from its Phase 1b study of ALKS 2680, aimed at treating Narcolepsy Type 2 and Idiopathic Hypersomnia.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:52 am

VALE

B of A Securities analyst Caio Ribeiro downgraded Vale (NYSE:VALE) from Buy to Neutral and reduced the price target from $20 to $13, indicating a more cautious outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:51 am